Blackstone and TPG Acquire Hologic for ~ $18.3B

Shots: Hologic has agreed to be acquired by Blackstone and TPG for up to $79 per share, valuing the deal at up to $18.3B. The deal is expected to close in H1'26 As per the deal, Blackstone and TPG will acquire all Hologic shares for $76 per share in cash plus a non-tradable CVR worth…

ByDipanshu DixitOctober 21, 2025

NEWS

BioCryst to Acquire Astria Therapeutics in ~$700M Cash-and-Stock Transaction

Shots: BioCryst Pharmaceuticals has entered into a definitive agreement to acquire Astria Therapeutics, strengthening its allergic & immunology portfolio As per the deal, Astria shareholders will receive $8.55 in cash + 0.59 BioCryst shares, valuing Astria at $13/share with an enterprise value of ~$700M (equity value: ~$920M), plus Astria shareholders will hold ~15% of pro…

ByRidhi RastogiOctober 15, 2025

NEWS

BMS to Strengthen its Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Shots: BMS has entered into a definitive agreement to acquire Orbital, strengthening & diversifying its cell therapy portfolio As per the deal, BMS will acquire Orbital, incl. its asset, OTX-201 & RNA platform, in an all-cash transaction of $1.5B OTX-201 is a preclinical circular RNA therapy encoding a CD19 CAR for in vivo expression delivered via…

ByRidhi RastogiOctober 13, 2025

NEWS

Novo Nordisk to Acquire Akero Therapeutics for ~$5.2B, Expanding its MASH Portfolio

Shots: Novo Nordisk will acquire Akero Therapeutics, incl. its lead asset efruxifermin (EFX), to expand its metabolic dysfunction-associated steatohepatitis (MASH) portfolio As per the deal, Novo Nordisk will acquire Akero for $54/share in an all-cash transaction totaling ~$4.7B, along with one non-tradeable CVR of $6/share (~$0.5B) tied to EFX’s US FDA approval for compensated cirrhosis due…

ByRidhi RastogiOctober 10, 2025

NEWS

Halozyme Therapeutics to Acquire Elektrofi for ~$900M, Expanding its Drug Delivery Offerings

Shots: Halozyme Therapeutics has entered into a definitive agreement to acquire Elektrofi, incl. its Hypercon technology, which enables biologic formulations at concentrations of 400-500mg/ml As per the deal, Elektrofi will receive $750M upfront, with up to three $50M milestone payments contingent on regulatory approvals of three separate Hypercon products; closing expected in Q4’25 As a result…

ByRidhi RastogiOctober 3, 2025

NEWS

Genmab to Acquire Merus for ~$8B

Shots: Genmab has entered into a transaction agreement to acquire Merus, incl. its lead asset petosemtamab, expanding its late-stage pipeline & accelerating Genmab’s shift to a wholly owned model As per the deal, Genmab will acquire Merus for $97 per share in an all-cash transaction, representing the deal value of ~$8B, with closing expected in the…

ByRidhi RastogiSeptember 29, 2025

NEWS

Pfizer Expands into Obesity Treatments with ~$7.3B Metsera Acquisition

Shots: Pfizer has entered into a definitive agreement to acquire Metsera, expanding to obesity & cardiometabolic market As per the deal, Metsera will receive $47.5/share, representing an enterprise value of ~$4.9B, plus a non-transferable CVR of ~$22.50/share tied to milestones: $5 on P-III start of MET-097i + MET-233i, $7 on FDA approval for MET-097i monotx.,…

ByRidhi RastogiSeptember 23, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Sep 15, 2025 – Sep 19, 2025)  

PharmaShots Weekly Snapshots (Sep 15, 2025 – Sep 19, 2025)   This week, PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, COVID-19, M&A and Biosimilars. Check out our full report below:   MAIA Biotechnology Reports P-II (THIO-101) Trial Data of Ateganosine Regimen for Advanced NSCLC Read More: MAIA Biotechnology Akeso Reports First…

ByRidhi RastogiSeptember 19, 2025

NEWS

Biogen to Acquire Alcyone Therapeutics to expand its drug delivery solutions Portfolio

Shots: Biogen has entered into a definitive agreement to acquire Alcyone Therapeutics, building on its partnership to advance ThecaFlex DRx As per the deal, Biogen will acquire Alcyone Therapeutics for $85M upfront + potential milestone payments tied to the development & approval of ThecaFlex DRx with nusinersen & other products. The deal gives Biogen full…

ByDipanshu DixitSeptember 19, 2025

NEWS

Roche to Acquire 89bio for ~$3.5B, Strengthening its CVRM Portfolio

Shots: Roche has entered into a definitive merger agreement to acquire 89bio, incl. its lead asset pegozafermin (FGF21 analog) for metabolic dysfunction-associated steatohepatitis, expanding cardiovascular, renal, & metabolic disease portfolio As per the deal, Roche will acquire 89bio for $14.5/share in an all-cash transaction totaling ~$2.4B, along with one non-tradeable CVR up to an…

ByRidhi RastogiSeptember 18, 2025

Blackstone and TPG Acquire Hologic for ~ $18.3B

BioCryst to Acquire Astria Therapeutics in ~$700M Cash-and-Stock Transaction

BMS to Strengthen its Cell Therapy Portfolio with $1.5B Orbital Therapeutics Acquisition

Novo Nordisk to Acquire Akero Therapeutics for ~$5.2B, Expanding its MASH Portfolio

Halozyme Therapeutics to Acquire Elektrofi for ~$900M, Expanding its Drug Delivery Offerings

Genmab to Acquire Merus for ~$8B

Pfizer Expands into Obesity Treatments with ~$7.3B Metsera Acquisition

PharmaShots Weekly Snapshots (Sep 15, 2025 – Sep 19, 2025)

Biogen to Acquire Alcyone Therapeutics to expand its drug delivery solutions Portfolio

Roche to Acquire 89bio for ~$3.5B, Strengthening its CVRM Portfolio

Contact US

FOLLOW US